Lumida
/LLY
⌘K
Eli Lilly and Co

Eli Lilly and Co

LLY
$1,115.70USD-0.65%-7.30 today

MARKET CAP

1.05T

P/E (TTM)

39.6x

FWD P/E

DAY RANGE

$1,113 – $1,131

52W RANGE

$712
$1,293

AI Summary

Stalk
Sell NowMedium

LLY is exhibiting a sequence of lower highs and lower lows under declining EMAs, reinforcing a bearish medium-term bias. Short-term trend remains down, with price rejecting rallies into the 9- and 20-day EMA zone despite extreme oversold readings. Execution is advised now on any bounce into the broken EMA region near the mid-$1,100s, with key invalidation being sustained acceptance above the 20-day EMA.

  • Q2 revenue $22.97B up 47.7% YoY, driven by Mounjaro and Zepbound
  • GLP-1 drugs make up ~65% of sales; Mounjaro surged 91% to $9.9B
  • Stretched valuation with low earnings yield and weak book-to-price metrics
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$28.3B$28.5B$34.1B$45.0B$65.2B
YoY %+15.4%+0.8%+19.6%+32.0%+44.7%
P / Sales8.9x11.6x15.7x15.5x14.8x
EV / Sales10.2x12.9x17.2x16.9x16.0x
Gross Profit, Adj.$21.0B$21.9B$27.0B$36.6B$54.1B
YoY %+10.2%+4.3%+23.4%+35.4%+47.8%
Margin %74.2%76.8%79.2%81.3%83.0%
EV / Gross Profit13.7x16.7x21.6x20.7x19.3x
EBITDA, Adj.$9.2B$9.8B$11.9B$18.8B$31.7B
YoY %+22.3%+6.7%+20.9%+58.7%+68.5%
Margin %32.5%34.3%34.7%41.8%48.6%
EV / EBITDA31.3x37.4x49.4x40.4x33.0x
EBIT$6.4B$7.1B$6.5B$12.9B$26.3B
YoY %+4.9%+12.1%-9.4%+99.8%+103.9%
Margin %22.4%25.0%18.9%28.6%40.4%
EV / EBIT45.2x51.5x90.6x58.9x39.7x
Net Income$5.6B$6.2B$5.2B$10.6B$20.6B
YoY %-9.9%+11.9%-16.1%+102.1%+94.9%
Net Margin19.7%21.9%15.4%23.5%31.7%
EPS (GAAP)$6.12$6.90$5.80$11.71$22.95
YoY %-9.9%+12.7%-15.9%+101.9%+96.0%